| Accession | Title | Series type(s) | Organism(s) | Samples | GDS | Supplementary | Contact | Release date |
|---|---|---|---|---|---|---|---|---|
 Filter
|
Expression profiling by array
|
TXT
|
Robert W Hoffman
|
|||||
| GSE88884 |
Gene expression changes in baseline SLE patients vs. healthy controls from two phase III trials (ILLUMINATE-1 and ILLUMINATE-2) of B cell activating factor blockade with tabalumab
|
|
1820 |
|
Robert W Hoffman | Oct 25, 2016 | ||
| GSE88885 |
Pharmacodynamic-induced changes in SLE Patients from the ILLUMINATE-1 phase III trial of B cell activating factor blockade with tabalumab
|
|
908 |
|
Robert W Hoffman | Oct 25, 2016 | ||
| GSE88886 |
Pharmacodynamic-induced changes in SLE Patients from the ILLUMINATE-2 phase III trial of B cell activating factor blockade with tabalumab
|
|
418 |
|
Robert W Hoffman | Oct 25, 2016 |
